Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/29200
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wong A. | en |
dc.date.accessioned | 2021-05-14T09:51:29Z | en |
dc.date.available | 2021-05-14T09:51:29Z | en |
dc.date.copyright | 2020 | en |
dc.date.created | 20200730 | en |
dc.date.issued | 2020-07-30 | en |
dc.identifier.citation | EMA - Emergency Medicine Australasia. 32 (4) (pp 697-699), 2020. Date of Publication: 01 Aug 2020. | en |
dc.identifier.issn | 1742-6731 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/29200 | en |
dc.description.abstract | Since December 2019, coronavirus disease (COVID-19) has been increasingly spreading from its origin in Wuhan, China to many countries around the world eventuating in morbidity and mortality affecting millions of people. This pandemic has proven to be a challenge given that there is no immediate cure, no vaccine is currently available and medications or treatments being used are still undergoing clinical trials. There have already been examples of self-medication and overdose. Clearly, there is a need to further define the efficacy of treatments used in the management of COVID-19. This evidence needs to be backed by large randomised-controlled clinical trials. In the meantime, there will no doubt be further off-label use of these medications by patients and practitioners and possibly related toxicity.Copyright © 2020 Australasian College for Emergency Medicine | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | Blackwell Publishing | en |
dc.relation.ispartof | EMA - Emergency Medicine Australasia | en |
dc.subject.mesh | bone marrow suppression | - |
dc.subject.mesh | China | - |
dc.subject.mesh | coma | - |
dc.subject.mesh | convulsion | - |
dc.subject.mesh | coronavirus disease 2019 | - |
dc.subject.mesh | diarrhea | - |
dc.subject.mesh | drug efficacy | - |
dc.subject.mesh | drug overdose | - |
dc.subject.mesh | drug research | - |
dc.subject.mesh | evidence based medicine | - |
dc.subject.mesh | gastrointestinal symptom | - |
dc.subject.mesh | headache | - |
dc.subject.mesh | heart arrhythmia | - |
dc.subject.mesh | hypertransaminasemia | - |
dc.subject.mesh | hypokalemia | - |
dc.subject.mesh | hypotension | - |
dc.subject.mesh | kidney dysfunction | - |
dc.subject.mesh | liver injury | - |
dc.subject.mesh | pancreatitis | - |
dc.subject.mesh | pandemic | - |
dc.subject.mesh | patient safety | - |
dc.subject.mesh | QT prolongation | - |
dc.subject.mesh | rash | - |
dc.subject.mesh | self medication | - |
dc.subject.mesh | virus load | - |
dc.subject.mesh | virus transmission | - |
dc.subject.mesh | activated carbon | - |
dc.subject.mesh | azithromycin [Adverse Drug Reaction] | - |
dc.subject.mesh | drug intoxication | - |
dc.subject.mesh | azithromycin | - |
dc.subject.mesh | ceftriaxone | - |
dc.subject.mesh | chloroquine [Adverse Drug Reaction] | - |
dc.subject.mesh | chloroquine | - |
dc.subject.mesh | atrioventricular block | - |
dc.subject.mesh | colchicine | - |
dc.subject.mesh | hydroxychloroquine [Adverse Drug Reaction] | - |
dc.subject.mesh | hydroxychloroquine | - |
dc.subject.mesh | ivermectin | - |
dc.subject.mesh | lopinavir plus ritonavir [Adverse Drug Reaction] | - |
dc.subject.mesh | lopinavir plus ritonavir | - |
dc.subject.mesh | remdesivir [Adverse Drug Reaction] | - |
dc.subject.mesh | remdesivir | - |
dc.subject.mesh | thalidomide | - |
dc.subject.mesh | tocilizumab [Adverse Drug Reaction] | - |
dc.subject.mesh | tocilizumab | - |
dc.title | COVID-19 and toxicity from potential treatments: Panacea or poison. | en |
dc.type | Article | en |
dc.identifier.affiliation | Monash University - School of Clinical Sciences at Monash Health | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1111/1742-6723.13537 | - |
dc.publisher.place | Australia | en |
dc.identifier.pubmedid | 32378805 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32378805] | en |
dc.identifier.source | 2004900692 | en |
dc.identifier.institution | (Wong) Victorian Poisons Information Centre, Austin Toxicology Unit and Emergency Department, Austin Health, Melbourne, VIC, Australia (Wong) Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia (Wong) Centre for Integrated Critical Care, Melbourne Medical School, The University of Melbourne, Melbourne, VIC, Australia | en |
dc.description.address | A. Wong, Victorian Poisons Information Centre, Austin Toxicology Unit and Emergency Department, Austin Health, Melbourne, VIC, Australia. E-mail: anselm.wong@austin.org.au A. Wong, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia. E-mail: anselm.wong@austin.org.au A. Wong, Centre for Integrated Critical Care, Melbourne Medical School, The University of Melbourne, Melbourne, VIC, Australia. E-mail: anselm.wong@austin.org.au | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2020 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | coronavirus COVID overdose toxicology | en |
dc.identifier.authoremail | Wong A.; anselm.wong@austin.org.au | en |
dc.description.grant | No: 1159907 Organization: (NHMRC) *National Health and Medical Research Council* Organization No: 501100000925 Country: Australia | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
crisitem.author.dept | Radiology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.